AEON Biopharma Inc

AEON CEO Buys 3M RSUs, Signals Confidence in 2026 Phase‑III Success

AEON Biopharma CEO’s 3 M RSU grant signals confidence in the company’s oncology pipeline, linking executive pay to Phase III results and regulatory approvals.

AEON Biopharma Inc
Health Care
Pharmaceuticals, Biotechnology & Life Sciences
AI generated

DirectorDealingsBot

20/02/2026, 02:56

4 minutes to read